The North American opioid epidemic: Current challenges and a call for treatment as prevention

Harm Reduction Journal

Volumn 14, Issue 1, 2017, Pages

  Vashishtha, Devesh ^a   Mittal, Maria Luisa ^a,b   Werb, Daniel ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Universidad Xochicalco Campus Tijuana   (Mexico)

Author keywords

Injection initiation; Medication assisted treatment; North America; Opioid epidemic; People who inject drugs; Treatment as Prevention

Indexed keywords

OPIATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANADA; CLINICAL RESEARCH; DRUG ADMINISTRATION; DRUG COST; DRUG MISUSE; DRUG TRAFFIC; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEXICO; NORTH AMERICAN; NOTE; OPIATE ADDICTION; PATIENT CARE; PRESCRIPTION; UNITED STATES; CLINICAL PRACTICE; HARM REDUCTION; NORTH AMERICA; STATISTICS AND NUMERICAL DATA;

HARM REDUCTION; HEALTH POLICY; HUMANS; NORTH AMERICA; OPIOID-RELATED DISORDERS; PRACTICE PATTERNS, PHYSICIANS';

EID: 85019169913     PISSN: None     EISSN: 14777517     Source Type: Journal    
DOI: 10.1186/s12954-017-0135-4     Document Type: Note

References (43)

1. Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am. J. Public Health [Internet]. 2015;105:e55-63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26066931.
2. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deathsUnited States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2016;64:137882. Available from: http://www.ncbi.nlm.nih.gov/pubmed/ 26720857.
3. Nosyk B, Douglas Anglin M, Brissette S, Kerr T, Marsh DC, Schackman BR, et al. A call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health Aff. 2013;32:14629.
4. Romero Mendoza M, Medina-Mora M, Gonzlez H, Vsquez J, Armas G, Magis C. Gua para el uso de metadona en usuarios adultos con VIH dependientes de la herona intravenosa. Mxico. 2016.
5. Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am. J. Public Health. 2009;99:2217.
6. Keeney E, Saucier R. Lowering the Threshold: Models of Accessible Methadone and Buprenorphine Treatment. 2010.
7. Statement by the Press Secretary on H.R. 34, the 21st Century Cures Act [Internet]. Off. Press Secr. 2016. Available from: https://www.whitehouse. gov/the-press-office/2016/11/30/statement-press-secretary-hr-34-21stcentury- cures-act.
8. Williams AR, Bisaga A. From AIDS to opioidshow to combat an epidemic. New Engl J Med. 2016;375:8135. Available from: http://www.nejm.org/doi/ 10.1056/NEJMp1604223.
9. Herzberg D, Guarino H, Mateu-Gelabert P, Bennett AS. Recurring epidemics of pharmaceutical drug abuse in America: time for an all-drug strategy. Am J Public Health. 2016;106:40810.
10. Murthy VH. Surgeon Generals Report on Alcohol, Drugs, and Health. JAMA [Internet]. Washington, DC; 2016; Available from: http://www.ncbi.nlm.nih. gov/pubmed/27854372.
11. Fanucchi L, Lofwall MR. Putting parity into practiceintegrating opioid-use disorder treatment into the hospital setting. N Engl J Med. 2016;375:8113. Available from: http://www.nejm.org/doi/10.1056/NEJMp1606157.
12. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic painUnited States, 2016. JAMA. 2016;315:162445.
13. Novick DM, Salsitz EA, Joseph H, Kreek MJ. Methadone medical maintenance: an early 21st-century perspective. J Addict Dis. 2015;34:226 37. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26110221.
14. Soubran Ortega L, Osorio Santos MA, Snchez Huesca R, Rtiz Mrquez IR, Len Len LM RSJ. Manual para la fijacin de cuotas de recuperacin en Centros de Integracin Juvenil (CIJ), Unidades De Hospitalizacin (UH) Y Unidades De Tratamiento Para Usuarios De Herona (UTUH) [Manual for setting recovery quotas at CIJ, UH, and UTUH]. [Internet]. A.C., Mexico; 2015. Available from: http://www.cij.gob.mx/Normateca/PDF/MFCRC-2015.pdf.
15. Dick AW, Pacula RL, Gordon AJ, Sorbero M, Burns RM, Leslie D, et al. Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002-11. Health Aff. 2015;34:102834. Available from: http://content.healthaffairs.org/content/34/6/1028.long.
16. Vignau J, Duhamel A, Catteau J, Legal G, Pho AH, Grailles I, et al. Practicebased buprenorphine maintenance treatment (BMT): how do French healthcare providers manage the opiate-addicted patients? J Subst Abuse Treat. 2001;21:13544. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/11728787.
17. Hersh D, Little SL, Gleghorn A. Integrating buprenorphine treatment into a public healthcare system: the San Francisco Department of Public Healths office-based Buprenorphine Pilot Program. J Psychoactive Drugs. 2011;43: 13645. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink. fcgi?dbfrom=pubmed&id=21858959&retmode=ref&cmd=prlinks.
18. Alford DP, LaBelle CT, Richardson JM, OConnell JJ, Hohl CA, Cheng DM, et al. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med. 2007;22:1716. Available from: http:// www.ncbi.nlm.nih.gov/pubmed/17356982.
19. LaBelle CT, Han SC, Bergeron A, Samet JH. Office-based opioid treatment with buprenorphine (OBOT-B): statewide implementation of the Massachusetts collaborative care model in community health centers. J Subst Abuse Treat. 2016;60:613. Available from: http://dx.doi.org/10.1016/j. jsat.2015.06.010.
20. Hansen H, Siegel C, Wanderling J, DiRocco D. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Drug Alcohol Depend. 2016;164: 1421. Available from: http://dx.doi.org/10.1016/j.drugalcdep.2016.03.028.
21. HHS announces new actions to combat opioid epidemic [Internet]. HHS Press Off. 2016 [cited 2016 Nov 20]. Available from: http://www.hhs.gov/ about/news/2016/07/06/hhs-announces-new-actions-combat-opioidepidemic. html.
22. Fiellin DA, Butler R, DOnofrio G, Brown RL, OConnor PG. The physicians role in caring for patients with substance use disorders: implications for medical education and training. Subst Abus. 2002;23:20722. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D= medc&NEWS=N&AN=23580996.
23. Isaacson JH, Fleming M, Kraus M, Kahn R, Mundt MA. National survey of training in substance use disorders in residency programs. A Stud Alcohol. 2000;61:912. Available from: http://www.ncbi.nlm.nih.gov/pubmed/ 11188498.
24. Friedman P, McCullough D, Saitz R. Screening and intervention for alcohol and illicit drug abuse. Arch Intern Med. 2001;161:24851.
25. Cunningham CO, Kunins HV, Roose RJ, Elam RT, Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007;22:13259.
26. Werb D, Mora MEM, Beletsky L, Rafful C, Mackey T, Arredondo J, et al. Mexicos drug policy reform: cutting edge success or crisis in the making? Int J Drug Policy. 2014;25. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/24974368.
27. Strathdee SA, Beletsky L, Kerr T. HIV, drugs and the legal environment. Int J Drug Policy. 2015;26:S2732. Available from: http://dx.doi.org/10.1016/j. drugpo.2014.09.001.
28. Strathdee SA, Arredondo J, Rocha T, Abramovitz D, Rolon ML, Patio Mandujano E, et al. A police education programme to integrate occupational safety and HIV prevention: protocol for a modified steppedwedge study design with parallel prospective cohorts to assess behavioural outcomes. BMJ Open. 2015;5:e008958. Available from: http://www.scopus. com/inward/record.url?eid=2-s2.0-84941560045&partnerID=tZOtx3y1.
29. Wood E, Spittal PM, Small W, Kerr T, Li K, Hogg RS, et al. Displacement of Canadas largest public illicit drug market in response to a police crackdown. CMAJ. 2004;170:15516.
30. Werb D, Kerr T, Nosyk B, Strathdee S, Montaner J, Wood E. The temporal relationship between drug supply indicators: an audit of international government surveillance systems. Br Med J. 2013;3:e003077.
31. Scott D. "Donald Trump's plan for heroin addiction: Build a wall-and offer some treatment." Stat News. 2016. Available from: https://www.statnews. com/2016/08/01/donald-trump-heroin-opioids-addiction/.
32. Godlee F, Hurley R. The war on drugs has failed: doctors should lead calls for drug policy reform. BMJ [Internet]. 2016;344. Available from: http://www. bmj.com/content/355/bmj.i6067.
33. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010; 375:101428.
34. Hansen H, Netherland J. Is the prescription opioid epidemic a white problem? Am J Public Health. 2016;106:21279. Available from: http://ajph. aphapublications.org/doi/10.2105/AJPH.2016.303483.
35. Wood E, Werb D, Kazatchkine M, Kerr T, Hankins C, Gorna R, et al. Vienna Declaration: a call for evidence-based drug policies. Lancet. 2010;376:3102. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20650517.
36. Werb D, Garfein R, Kerr T, Davidson P, Roux P, Jauffret-Roustide M, et al. A socio-structural approach to preventing injection drug use initiation: rationale for the PRIMER study. Harm Reduct J. 2016;13:25. Available from: http://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-016- 0114-1.
37. Banta-Green CJ, Beletsky L, Schoeppe JA, Coffin PO, Kuszler PC. Police officers and paramedics experiences with overdose and their knowledge and opinions of Washington States drug overdose-naloxone-Good Samaritan law. J Urban Health. 2013;90:110211. Available from: http://www. ncbi.nlm.nih.gov/pubmed/23900788.
38. Porter N. The state of sentencing 2015: developments in policy and practice [Internet]. Washington, D.C.; Available from: http://www.sentencingproject. org/publications/the-state-of-sentencing-2015-developments-in-policy-andpractice/.
39. Netherland J, Hansen HB. The war on drugs that wasnt: wasted whiteness, Dirty Doctors, and race in media coverage of prescription opioid misuse. Cult. Med. Psychiatry [Internet]. Springer US; 2016;40:66486. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27272904.
40. White J, Bell J, Saunders JB, Williamson P, Makowska M, Farquharson A, et al. Open-label dose-finding trial of buprenorphine implants (probuphine) for treatment of heroin dependence. Drug Alcohol Depend. 2009;103:3743.
41. Montaner JSG, Lima VD, Harrigan PR, Lourenco L, Yip B, Nosyk B, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and hiv transmission: the HIV treatment as prevention experience in a Canadian setting. PLoS ONE. 2014;9:110.
42. Dubois-arber F, Balthasar H, Huissoud T, Zobel F, Arnaud S, Samitca S, et al. Trends in drug consumption and risk of transmission of HIV and hepatitis C virus among injecting drug users in Switzerland, 1993-2006. Eurosurveillance. 2008;13:16.
43. Mittal M, Vashishtha D, Sun S, Jain S, Garfein R, Strathdee S, et al. Opioid Substitution Therapy and Initiation into Injection Drugs Use in San Diego, CA. Present. Seattle: Conf. Retroviruses Opportunistic Infect; 2017.